← Back to Search

Other

Pharmacogenomics and Pharmacometabolomics of Acamprosate Treatment Outcome

Phase 4
Waitlist Available
Led By Victor M Karpyak
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up will be defined as continuous sobriety (yes/no) during 3 months of treatment
Awards & highlights
Approved for 5 Other Conditions
Pivotal Trial
All Individual Drugs Already Approved
Drug Has Already Been Approved

Summary

This trial is investigating the use of acamprosate, a medication that helps reduce cravings for alcohol, in individuals with Alcohol Use Disorders (AUDs). These patients often relapse after treatment, and new methods are needed to help them stay sober. The study aims to find indicators that can predict who will benefit from acamprosate. Acamprosate is a relatively new drug that has been shown to help maintain abstinence in alcohol-dependent patients by reducing cravings.

Eligible Conditions
  • Alcoholism

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~will be defined as continuous sobriety (yes/no) during 3 months of treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and will be defined as continuous sobriety (yes/no) during 3 months of treatment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Participants With Continuous Sobriety According to Alcohol Timeline Follow Back
Secondary study objectives
Cumulative Abstinence Duration - Timeline Follow Back
Day Until First Alcohol Use (Relapse) - Alcohol Timeline Follow Back
Days Until First Relapse (Heavy Relapse) - Timeline Follow Back

Awards & Highlights

Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: AcamprosateActive Control1 Intervention
All participants will be randomized to receive acamprosate or placebo in a double-blinded placebo-controlled trial. The most common side effect associated with acamprosate use is diarrhea, which occurs in approximately 16% of patients. Other frequently occurring side effects include asthenia, nausea, pruritus, and flatulence, headache, abdominal pain, flu syndrome, edema, weight gain, and myalgia.
Group II: PlaceboPlacebo Group1 Intervention
All participants will be randomized to receive acamprosate or placebo in a double-blinded placebo-controlled trial.

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,362 Previous Clinical Trials
3,065,833 Total Patients Enrolled
8 Trials studying Alcoholism
1,198 Patients Enrolled for Alcoholism
National Institute on Alcohol Abuse and Alcoholism (NIAAA)NIH
839 Previous Clinical Trials
1,083,483 Total Patients Enrolled
459 Trials studying Alcoholism
823,543 Patients Enrolled for Alcoholism
Victor M KarpyakPrincipal InvestigatorMayo Clinic
Victor M Karpyak, MD, Ph.D.Principal InvestigatorMayo Clinic

Media Library

Acamprosate (Other) Clinical Trial Eligibility Overview. Trial Name: NCT03818191 — Phase 4
Alcoholism Research Study Groups: Placebo, Acamprosate
Alcoholism Clinical Trial 2023: Acamprosate Highlights & Side Effects. Trial Name: NCT03818191 — Phase 4
Acamprosate (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03818191 — Phase 4
~45 spots leftby Dec 2025